Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale. Anti-BCMA antibody-drug conjugate (ADC) Blenrep (belantamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback